

POTASSIUM CHLORIDE IN DEXTROSE- dextrose monohydrate and potassium chloride injection, solution injection, solution
ICU Medical Inc.

POTASSIUM CHLORIDE
in Dextrose Injection, USP

20 mEq/liter Potassium Chloride in 5% Dextrose Injection

Rx only

DESCRIPTION


Potassium Chloride in Dextrose Injection, USP is a sterile and nonpyrogenic solution in water for injection. This solution is for administration by intravenous infusion only.

See Table for summary of content and characteristics of this solution.

This solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only for use as a single-dose injection. When smaller doses are required the unused portion should be discarded.

This solution is a parenteral fluid, nutrient and electrolyte replenisher.

Dextrose, USP is chemically designated D-glucose monohydrate ($C_6H_{12}O_6 \cdot H_2O$), a hexose sugar freely soluble in water. It has the following structural formula:



Potassium Chloride, USP is chemically designated KCl, a white granular powder freely soluble in water.

Water for Injection, USP is chemically designated H₂O.

The flexible plastic container is fabricated from a specially formulated polyvinyl chloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.

CLINICAL PHARMACOLOGY

When administered intravenously, this solution provides a source of water and potassium chloride with carbohydrate.

Solutions containing carbohydrate in the form of dextrose restore blood glucose levels and provide calories. Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein-sparing action. Dextrose injected parenterally undergoes oxidation to carbon dioxide and water.

Intravenous solutions containing potassium chloride are particularly intended to provide needed potassium cation (K^+). Potassium is the chief cation of body cells (160 mEq/liter of intracellular water). It is found in low concentration in plasma and extracellular fluids (3.5 to 5.0 mEq/liter in a healthy adult). Potassium plays an important role in electrolyte balance. Normally about 80 to 90% of the potassium intake is excreted in the urine; the remainder in the stools and to a small extent, in the perspiration. The kidney does not conserve potassium well so that during fasting or in patients on a potassium-free diet, potassium loss from the body continues resulting in potassium depletion. A deficiency of either potassium, or chloride will lead to a deficit of the other.

Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).

Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na^+) plays a major role in maintaining physiologic equilibrium.

INDICATIONS AND USAGE

This solution is indicated in patients requiring parenteral administration of potassium chloride with minimal carbohydrate calories.

CONTRAINDICATIONS

Solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered.

WARNINGS

Solutions which contain potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present.

To avoid potassium intoxication, do not infuse these solutions rapidly. In patients with severe renal insufficiency or adrenal insufficiency, administration of potassium chloride may cause potassium intoxication.

In patients with diminished renal function, administration of solutions containing potassium ions may result in potassium retention.

The intravenous administration of this solution can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.

The risk of dilutional states is inversely proportional to the electrolyte concentration of administered parenteral solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.

PRECAUTIONS

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.

Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions, to patients receiving corticosteroids or corticotropin.

Potassium replacement therapy should be guided primarily by serial electrocardiograms. Plasma potassium levels are not necessarily indicative of tissue potassium levels.

High plasma concentrations of potassium may cause death through cardiac depression, arrhythmias or arrest.

Potassium-containing solutions should be used with caution in the presence of cardiac disease, particularly in digitalized patients or in the presence of renal disease.

Care should be exercised to insure that the needle (or catheter) is well within the lumen of the vein and that extravasation does not occur.

Do not administer unless solution is clear and container is undamaged. Discard unused portion.

Pregnancy Category C

Animal reproduction studies have not been conducted with dextrose or potassium chloride. It is also not known whether dextrose or potassium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dextrose or potassium chloride should be given to a pregnant woman only if clearly needed.

Pediatric use

The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. In neonates or very small infants the volume of fluid may affect fluid and electrolyte balance.

Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants.

In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.

ADVERSE REACTIONS

Reactions which may occur because of the solutions or technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Nausea, vomiting, abdominal pain and diarrhea have been reported with potassium therapy. The signs and symptoms of potassium intoxication include paresthesias of the extremities, flaccid paralysis, listlessness, mental confusion, weakness and heaviness of the legs, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities such as disappearance of P waves, spreading and slurring of the QRS

complex with development of a biphasic curve and cardiac arrest.

Potassium-containing solutions are intrinsically irritating to tissues. Therefore, extreme care should be taken to avoid perivascular infiltration. Local tissue necrosis and subsequent sloughing may result if extravasation occurs. Chemical phlebitis and venospasm have also been reported.

Should perivascular infiltration occur, I.V. administration at that site should be discontinued at once. Local infiltration of the affected area with procaine hydrochloride, 1%, to which hyaluronidase may be added, will often reduce venospasm and dilute the potassium remaining in the tissues locally. Local application of heat may also be helpful.

OVERDOSAGE

In the event of potassium overdosage, discontinue the infusion immediately and institute intensive corrective therapy to reduce serum potassium levels. See **WARNINGS** and **PRECAUTIONS**.

DOSAGE AND ADMINISTRATION

This solution should be administered only by intravenous infusion and as directed by the physician. The dose and rate of injection are dependent upon the age, weight and clinical condition of the patient. If the serum potassium level is greater than 2.5 mEq/liter, potassium should be given at a rate not to exceed 10 mEq/hour in a concentration less than 30 mEq/liter. Somewhat faster rates and greater concentrations (usually up to 40 mEq/liter) of potassium may be indicated in patients with more severe potassium deficiency. The total 24-hour dose should not generally exceed 200 mEq of potassium.

As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See **PRECAUTIONS**.

Drug Interactions

Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.

INSTRUCTIONS FOR USE

To Open

Tear outer wrap at notch and remove solution container. If supplemental medication is desired, follow directions below before preparing for administration. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.

To Add Medication

1. Prepare additive port.
2. Using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. Withdraw needle after injecting medication.
3. The additive port may be protected by covering with an additive cap.
4. Mix container contents thoroughly.

**Preparation for Administration
(Use aseptic technique)**

1. Close flow control clamp of administration set.
2. Remove cover from outlet port at bottom of container.
3. Insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. **NOTE:** When using a vented administration set, replace bacterial retentive air filter with piercing pin cover. Insert piercing pin with twisting motion until shoulder of air filter housing rests against the outlet port flange.
4. Suspend container from hanger.
5. Squeeze and release drip chamber to establish proper fluid level in chamber.
6. Attach venipuncture device to set.
7. Open clamp to expel air from set and venipuncture device. Close clamp.
8. Perform venipuncture.
9. Regulate rate of administration with flow control clamp.

WARNING: Do not use flexible container in series connections.

HOW SUPPLIED

Potassium Chloride in Dextrose Injection, USP solution is supplied in single-dose flexible plastic containers. See Table:

Table of Contents and Characteristics

		Grams/100 mL			Per 1000 mL					
mEq Potassium	Size (mL)	NDC No.	Dextrose Hydrous	Potassium Chloride	Potassium (K+)	Chloride (Cl ⁻)	Caloric Value	Calculated Osmolarity (mOsmol)	Tonicity	pH
20 mEq	1000	0409-7905-09	5	0.149	20 mEq	20 mEq	170	292	isotonic	4.3 (3.5 to 6.5)
20 mEq	1000	0990-7905-09	5	0.149	20 mEq	20 mEq	170	292	isotonic	4.3 (3.5 to 6.5)

ICU Medical is transitioning NDC codes from the "0409" to "0990" labeler code. Both NDC codes are expected to be in the market for a period of time.

May contain HCl for pH adjustment.

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing.

Revised: March, 2020

IFU0000169

ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

icumedical

PRINCIPAL DISPLAY PANEL - 1000 mL Bag Label

20 mEq POTASSIUM

1000 mL
NDC 0990-7905-09

20 mEq
Potassium
Chloride
in 5% Dextrose Inj., USP

EACH 100 mL CONTAINS POTASSIUM
CHLORIDE 149 mg; DEXTROSE, HYDROUS
5 g IN WATER FOR INJECTION. MAY
CONTAIN HCl FOR pH ADJUSTMENT.
ELECTROLYTES PER 1000 mL (NOT
INCLUDING IONS FOR pH ADJUSTMENT):
POTASSIUM 20 mEq; CHLORIDE 20 mEq.
292 mOsmol/LITER (CALC). pH 4.3 (3.5 TO 6.5)

ADDITIVES MAY BE INCOMPATIBLE.
CONSULT WITH PHARMACIST, IF
AVAILABLE. WHEN INTRODUCING
ADDITIVES, USE ASEPTIC TECHNIQUE,
MIX THOROUGHLY AND DO NOT STORE.

SINGLE-DOSE CONTAINER. FOR I.V. USE.
USUAL DOSAGE: SEE INSERT. STERILE,
NONPYROGENIC. USE ONLY IF SOLUTION IS
CLEAR AND CONTAINER IS UNDEMANAGED.
MUST NOT BE USED IN SERIES
CONNECTIONS.

Rx ONLY

3
v
CONTAINS DEHP

IMP0000051
ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

icumedical

20 mEq POTASSIUM

1000 mL

NDC 0990-7905-09

20 mEq Potassium Chloride in 5% Dextrose Inj., USP

EACH 100 mL CONTAINS POTASSIUM CHLORIDE 149 mg; DEXTROSE, HYDROUS 5 g IN WATER FOR INJECTION. MAY CONTAIN HCl FOR pH ADJUSTMENT. ELECTROLYTES PER 1000 mL (NOT INCLUDING IONS FOR pH ADJUSTMENT): POTASSIUM 20 mEq; CHLORIDE 20 mEq. 292 mOsmol/LITER (CALC). pH 4.3 (3.5 TO 6.5)

ADDITIVES MAY BE INCOMPATIBLE. CONSULT WITH PHARMACIST, IF AVAILABLE. WHEN INTRODUCING ADDITIVES, USE ASEPTIC TECHNIQUE, MIX THOROUGHLY AND DO NOT STORE.

SINGLE-DOSE CONTAINER. FOR I.V. USE. USUAL DOSAGE: SEE INSERT. STERILE, NONPYROGENIC. USE ONLY IF SOLUTION IS CLEAR AND CONTAINER IS UNDAMAGED. MUST NOT BE USED IN SERIES CONNECTIONS.



CONTAINS DEHP

Rx ONLY



IMPO000051

icumedical

ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

1
2
3
4
5
6
7
8
9

POTASSIUM CHLORIDE IN DEXTROSE

dextrose monohydrate and potassium chloride injection, solution injection, solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0990-7905
Route of Administration	INTRAVENOUS		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SLOG7R00K)	DEXTROSE MONOHYDRATE	5 g in 100 mL

POTASSIUM CHLORIDE (UNII: 660YQ98I10) (POTASSIUM CATION - UNII:295O53K152, CHLORIDE ION - UNII:Q32Z N48698)	POTASSIUM CHLORIDE	0.149 g in 100 mL
--	--------------------	----------------------

Inactive Ingredients

Ingredient Name	Strength
WATER (UNII: 059QF0KO0R)	
HYDROCHLORIC ACID (UNII: QTT17582CB)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0990-7905-09	12 in 1 CASE	11/20/2020	
1		1 in 1 POUCH		
1		1000 mL in 1 BAG; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA018371	11/20/2020	

Labeler - ICU Medical Inc. (118380146)

Revised: 11/2020

ICU Medical Inc.